1.Analysis of Clinical Response on Cardiac Resynchronization Therapy in Patients of Chronic Heart Failure With Different QRS Wave Morphology
Liguo JIAN ; Shichao LIU ; Tongbin DING ; Jiangtao ZHAO ; Dong CHENG ; Yujie ZHAO ; Yiqiang YUAN
Chinese Circulation Journal 2015;(9):867-871
Objective: To explore the clinical response on cardiac resynchronization therapy (CRT) in patients of chronic heart failure (CHF) with different QRS wave morphology. Methods: A total of 52 CHF patients received CRT in our hospital and the Seventh People's Hospital of Zhengzhou City from 2010-03 to 2013-07 were retrospectively studied. The patients were divided into 3 groups: True-complete left bundle branch block (t-CLBBB) group,n=20, Classic LBBB (CLBBB) group,n=15 and IVCD group,n=17. The general clinical condition, the indexes of echocardiography at 6 months of follow-up study including left ventricular end diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), NYHA classiifcation and 6-MWT were examined and compared among different groups. Results: In general clinical condition, the ratio of non-ischemic heart disease patients in t-CLBBB group was higher than those in CLBBB group and IVCD group, allP<0.05. By 6 months follow-up study, LVEDD in t-CLBBB group (62.6 ± 8.9) mm was lower than those in CLBBB group (70.0 ± 8.9) mm and IVCD group (72.8 ± 8.0) mm, LVEF was higher in t-CLBBB group (38.5 ± 6.2) % than those in CLBBB group (31.7 ± 6.7) % and IVCD group (30.1 ± 6.7) %. NYHA classiifcation in t-CLBBB group (2.00 ± 0.45) grade was lower than those in CLBBB group (2.73 ± 0.80) grade and IVCD group (3.12 ± 0.78) grade . 6-MWT in t-CLBBB group (302.0 ± 57.9) m was longer than those in CLBBB group (257.3 ± 59.0) m and IVCD group (220.2 ± 57.9) m, allP<0.05. Conclusion: CRT is an effective method for treating CHD patients, different QRS morphology may have different response, the patients with t-CLBBB would make better response.
2.Effect of Aidi injection on T lymphocyte subsets and quality of life in patients with colon cancer
Guiyang WU ; Zaiping CHEN ; Fubo YE ; Xiongwen ZHU ; Shichao YUAN
China Modern Doctor 2018;56(13):10-13
Objective To investigate the changes of T lymphocyte subsets and quality of life after administrating Aidi injection in patients with colon cancer. Methods A total of 86 patients with colon cancer admitted to our hospital from February 2015 to May 2017 were enrolled in this study. The patients were divided into chemotherapy group (43 patients, conventional therapy) and combination group (43 cases,conventional chemotherapy+Aidi injection) by random number table. Compared the recent curative effect, level of T lymphocyte subsets, changes of quality of life and adverse reactions before and after treatment. Results There were significant differences in the distribution of CR, PR, SD and PD between the combination group and the chemotherapy group(P<0. 05). The former had a clinical benefit rate of 72. 09% and the latter was 51. 16%. The difference was statistically significant(P<0. 05). There was no significant difference in the level of T lymphocyte subsets and quality of life in the combination group after treatment(P>0. 05). The CD3+, CD4+, CD4+/CD8+ and scores of quality of life in the chemotherapy group were significantly lower(P<0. 05) after treatment, CD8+ increased in both groups, and there was statistical difference between the combination group and the chemotherapy group after treatment(P<0. 05). The incidence of adverse reactions in the combination group was lower than that in the chemotherapy group(P<0. 05) and the difference of classification comparison was also statistically significant(P<0. 05). Conclusion The use of Aidi injection in colon cancer patients with chemotherapy can improve the short-term curative effect, avoid the damage of immune function and reduction of the quality of life, and relieve and reduce the adverse reactions caused by chemotherapy.
3.Genomic and Transcriptomic Characterization Revealed the High Sensitivity of Targeted Therapy and Immunotherapy in a Subset of Endometrial Stromal Sarcoma
Nan KANG ; Yinli ZHANG ; Shichao GUO ; Ran CHEN ; Fangzhou KONG ; Shuchun WANG ; Mingming YUAN ; Rongrong CHEN ; Danhua SHEN ; Jianliu WANG
Cancer Research and Treatment 2023;55(3):978-991
Purpose:
The unique chromosomal rearrangements of endometrial stromal sarcoma (ESS) make it possible to distinguish high-grade ESS (HGESS) and low-grade ESS (LGESS) from the molecular perspective. Analysis of ESS at the genomic and transcriptomic levels can help us achieve accurate diagnosis of ESS and provide potential therapy options for ESS patients.
Materials and Methods:
A total of 36 ESS patients who conducted DNA- and/or RNA-based next-generation sequencing were retrospectively enrolled in this study. The molecular characteristics of ESS at genomic and transcriptomic levels, including mutational spectrum, fusion profiles, gene expression and pathway enrichment analysis and features about immune microenvironment were comprehensively explored.
Results:
TP53 and DNMT3A mutations were the most frequent mutations. The classical fusions frequently found in HGESS (ZC3H7B-BCOR and NUTM2B-YWHAE) and LGESS (JAZF1-SUZ12) were detected in our cohort. CCND1 was significantly up-regulated in HGESS, while the expression of GPER1 and PGR encoding estrogen receptor (ER) and progesterone receptor (PR) did not differ significantly between HGESS and LGESS. Actionable mutations enriched in homologous recombination repair, cell cycle, and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathways were detected in 60% of HGESS patients. Genes with up-regulated expression in HGESS were significantly enriched in five immune-related pathways. Most HGESS patients (85.7%) had positive predictors of immunotherapy efficacy. Moreover, immune microenvironment analysis showed that HGESS had relatively high immune infiltration. The degree of immune infiltration in HGESS patients with ZC3H7B-BCOR fusion was relatively higher than that of those with NUTM2B-YWHAE fusion.
Conclusion
This study investigated the molecular characteristics of ESS patients at the genomic and transcriptomic levels and revealed the potentially high sensitivity of targeted therapy and immunotherapy in a subset of HGESS with specific molecular features, providing a basis for guiding decision-making of treatment and the design of future clinical trials on precision therapy.
4.Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China.
Xueli BAI ; Riga SU ; Tao MA ; Shichao SHEN ; Guogang LI ; Jianying LOU ; Shunliang GAO ; Risheng QUE ; Ying YUAN ; Risheng YU ; Qichun WEI ; Tingbo LIANG
Chinese Journal of Surgery 2016;54(4):270-275
OBJECTIVETo explore efficacy and safety of modified FOLFIRINOX (mFOLFIRINOX) regimen by dose attenuation in locally advanced pancreatic cancer (LAPC) and metastatic pancreatic cancer(MPC).
METHODSBetween April 2014 and October 2015, 35 patients with LAPC (n=18) or MPC (n=17) were treated with mFOLFIRINOX regimen (irinotecan 135 mg/m(2), oxaliplatin 68 mg/m(2), 5-FU 2 400 mg/m(2), no bolus of 5-FU, leucovorin 400 mg/m(2)) in the Second Affiliated Hospital of Zhejiang University School of Medicine. The primary end point was progression free survival. The second end points were overall survival, objective response rate, adverse effects, surgical resection rate for LAPC.
RESULTSAmong 35 patients, 6 patients (17.1%) who dropped out and received less than 2 cycles were excluded for response analysis. Among the other 29 patients, 9 patients had grade 3 or 4 adverse effects. No patients ceased treatment due to adverse effects. The 29 patients received 5 (2-13) cycles were evaluated by efficacy and found partial remission in 16 cases, stable disease in 10 cases, progression disease in 3 cases. Response rate was 55.2%. Nine patients with LAPC accomplished surgery after neoadjuvant treatment without perioperative complication and death, and 6 patients accepted R0 resection.
CONCLUSIONSThe mFOLFIRINOX regimen used in the study is well-tolerated in Chinese population with high treatment efficacy on patients with LAPC and MPC. Further investigation of efficacy and adverse effects on more advanced pancreatic cancer patients is necessary.
Antineoplastic Combined Chemotherapy Protocols ; Camptothecin ; administration & dosage ; analogs & derivatives ; Disease Progression ; Disease-Free Survival ; Fluorouracil ; administration & dosage ; Humans ; Leucovorin ; administration & dosage ; Neoadjuvant Therapy ; Organoplatinum Compounds ; administration & dosage ; Pancreatic Neoplasms ; drug therapy ; Tertiary Care Centers ; Treatment Outcome
5.Visualization analysis of domestic violence research based on Web of Science database
Yijun YUAN ; Maorong HU ; Yong HAN ; Shichao LIAO ; Haoyu YANG
Sichuan Mental Health 2022;35(2):165-170
ObjectiveTo understand the current status and development of research on the subject of domestic violence, and to grasp the main research hotspots in the field. MethodsThe literature in the core database of Web of Science were retrieved, and 20 417 literature related to domestic violence from January 1966 to September 2021 were sorted by using the CiteSpace software, and the number of literature, authors, research institutions and keywords were analyzed. Results①The volume of literature on domestic violence grown rapidly since 2015. ②Among the authors, Kelsey Hegarty, Gene Feder and others had large number of publications on domestic violence, moreover, the authors' cooperation formed some small collaborative groups and research groups of a certain scale. ③The research institutions were closely collaborating, among which University of North Carolina was the institution of highest number of publications, and Boston University was the institution with the strongest research centrality. ④Hot keywords kept developing and changing, and the current hot keywords were mainly dating violence, sexual violence and the perception and perpetration of domestic violence. ConclusionThe field of domestic violence has been studied by a large number of researchers and has given rise to many research hotspots.
6.Study on the accuracy of oxygen concentration of modified oxygen treatment with Venturi and humidity system.
Qiang WEI ; Bingyu QIN ; Guojun HE ; Yuanyuan WU ; Yuan SHI ; Weitao SUN ; Mengjuan JING ; Shichao ZHU ; Huanzhang SHAO
Chinese Critical Care Medicine 2018;30(7):677-680
OBJECTIVE:
To verify the accuracy of oxygen concentration (FiO2) of modified oxygen treatment with Venturi and humidity system.
METHODS:
Patients just after ventilator weaning and before the removal of tracheal intubation/tracheotomy tube, who admitted to the intensive care unit (ICU) of Henan Provincial People's Hospital from May 1st to December 15th in 2017, were enrolled. All patients were given a modified oxygen treatment with Venturi and humidity system, and the oxygen flow rate (Flow) of the Venturi device and the oretical value of FiO2 were adjusted according to the patient's condition. Patients were divided into five groups based on doctor's orders: Flow 3 L/min FiO2 0.24, Flow 3 L/min FiO2 0.26, Flow 6 L/min FiO2 0.28, Flow 6 L/min FiO2 0.30, Flow 9 L/min FiO2 0.35. The value of FiO2 at the inhalation end of patients of each group was measured by TSI airflow analyzer, and the consistency between the measured value of FiO2 at the inhalation end and the FiO2 marked value of Venturi was compared and analyzed.
RESULTS:
When the FiO2 theoretical value of Venturi were adjusted to 0.24, 0.26, 0.28, 0.30, and 0.35, the measured values of FiO2 at the inhalation end of patients were 0.38±0.05, 0.38±0.05, 0.40±0.04, 0.41±0.04, and 0.77±0.11, respectively, which were all significantly higher than the theoretical value of FiO2 (all P < 0.01). The difference between the measured value of FiO2 at the inhalation side and the FiO2 value of the Venturi annotated and the difference rate were both "V"-shaped, both of which decreased with the increase in theoretical value of FiO2 to a Flow of 9 L/min and a theoretical value of FiO2 0.35, the accuracy was the worst, with the FiO2 difference of 0.42±0.11, and the FiO2 difference rate of (121.6±36.5)%.
CONCLUSIONS
There is a difference between the measured value and the theoretical value of FiO2 at the inhalation end of the modified Venturi oxygen therapy humidification system, which needs to be paid attention to during clinical oxygen therapy.
Humans
;
Humidity
;
Oxygen/analysis*
;
Oxygen Inhalation Therapy
;
Respiration, Artificial
;
Ventilator Weaning
7. Study on the accuracy of oxygen concentration of modified oxygen treatment with Venturi and humidity system
Qiang WEI ; Bingyu QIN ; Guojun HE ; Yuanyuan WU ; Yuan SHI ; Weitao SUN ; Mengjuan JING ; Shichao ZHU ; Huanzhang SHAO
Chinese Critical Care Medicine 2018;30(7):677-680
Objective:
To verify the accuracy of oxygen concentration (FiO2) of modified oxygen treatment with Venturi and humidity system.
Methods:
Patients just after ventilator weaning and before the removal of tracheal intubation/tracheotomy tube, who admitted to the intensive care unit (ICU) of Henan Provincial People's Hospital from May 1st to December 15th in 2017, were enrolled. All patients were given a modified oxygen treatment with Venturi and humidity system, and the oxygen flow rate (Flow) of the Venturi device and the oretical value of FiO2 were adjusted according to the patient's condition. Patients were divided into five groups based on doctor's orders: Flow 3 L/min FiO2 0.24, Flow 3 L/min FiO2 0.26, Flow 6 L/min FiO2 0.28, Flow 6 L/min FiO2 0.30, Flow 9 L/min FiO2 0.35. The value of FiO2 at the inhalation end of patients of each group was measured by TSI airflow analyzer, and the consistency between the measured value of FiO2 at the inhalation end and the FiO2 marked value of Venturi was compared and analyzed.
Results:
When the FiO2 theoretical value of Venturi were adjusted to 0.24, 0.26, 0.28, 0.30, and 0.35, the measured values of FiO2 at the inhalation end of patients were 0.38±0.05, 0.38±0.05, 0.40±0.04, 0.41±0.04, and 0.77±0.11, respectively, which were all significantly higher than the theoretical value of FiO2 (all